Page 101 - Read Online

Page 18 of 18 Kouroumalis et al. Hepatoma Res 2018;4:34 I http://dx.doi.org/10.20517/2394-5079.2018.33

135. Becker G, Allgaier HP, Olschewski M, Zahringer A, Blum HE; HECTOR Study Group. Long-acting octreotide versus placebo for
treatment of advanced HCC: a randomized controlled double-blind study. Hepatology 2007;45:9-15.
136. Barbare JC, Bouché O, Bonnetain F, Dahan L, Lombard-Bohas C, Faroux R, Raoul JL, Cattan S, Lemoine A, Blanc JF, Bronowicki JP,
Zarski JP, Cazorla S, Gargot D, Thevenot T, Diaz E, Bastie A, Aparicio T, Bedenne L. Treatment of advanced hepatocellular carcinoma
with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study. Eur J Cancer 2009;45:1788-97.
137. Sanoff HK, Kim R, Ivanova A, Alistar A, McRee AJ, O’Neil BH. Everolimus and pasireotide for advanced and metastatic hepatocellular
carcinoma. Invest New Drugs 2015;33:505-9.
138. Feun LG, Wangpaichitr M, Li YY, Kwon D, Richman SP, Hosein PJ, Savaraj N. Phase II trial of SOM230 (pasireotide LAR) in patients
with unresectable hepatocellular carcinoma. J Hepatocell Carcinoma 2018;5:9-15.
139. Ji XQ, Ruan XJ, Chen H, Chen G, Li SH, Yu B. Somatostatin analogues in advanced hepatocellular carcinoma: an updated systematic
review and meta-analysis of randomized controlled trials. Med Sci Monit 2011;17:RA169-76.
140. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update.
Hepatology 2011;53:1020-2.
141. Xiong ZP, Huang F, Lu MH. Association between insulin-like growth factor-2 expression and prognosis after transcatheter arterial
chemoembolization and octreotide in patients with hepatocellar carcinoma. Asian Pacific J Cancer Prev 2012;13:3191-4.
142. Qian J, Yao D, Dong Z, Wu W, Qiu L, Yao N, Li S, Bian Y, Wang Z, Shi G. Characteristics of hepatic IGF-II expression and monitored
levels of circulating IGF-II mRNA in metastasis of hepatocellular carcinoma. Am J Clin Pathol 2010;134:799-806.